Three minor strokes and one TIA occurred. In 17/20 patients the thrombus resolved following anticoagulatlon therapy with heparin or wariarin. In 3120 patients the thrombus had to be removed surgically.
the Amplatzer on one hand and the CardioSEAL, the STARFlex and the PFO-Star occluder on the other hand was signlflcant (p < 0.05).
Prethrombotic disorders w:xe found in 2 PFO patients (thrombocytosis and hyperactivity of Factor VIII), post procedure atrial fibrillation in 4, persistent atrial septal aneurysm despite device implantation in 4. dewce arm fractures in 3. Significant predictors of thrombus were atrial fibrillation and persistent septum aneurysm.
Three minor strokes and one TIA occurred. In 17/20 patients the thrombus resolved following anticoagulatlon therapy with heparin or wariarin. In 3120 patients the thrombus had to be removed surgically.
Conclusion:
The incidence of thrombus formation on closure devices is low. In most of the patients the thrombus resolved under anticoagulation therapy without clinical consequences.
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Favorable Right Heart Remodeling After Atrial Septal Defect Device Closure Even in the Over-60 Age Group
Lorna Swan Chetan Varma, James W. Yip, Matthew Warr, Lee N. Benson, Peter
McLaughlin, Toronto General Hospital, Toronto, ON, Canada Background: The degree to which the right heart remodels after atrial septal defect (ASD) closure is believed to be proportional to the age at the time of the procedure. It is unknown if there is a chronological limit to this process and whither closure over the age of 60 or 70 years is still associated with a beneficial effect in terms of right heart morphology. The aim of this study was to assess the safely and efficacy of device closure in those over 60 years of age. The right heart shows signs of remodelling even in these elderly subjects.
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Single The design oh previously used devices for transcatheter closure of perimembranous ventricular septal defects (PMVSDs) is not ideal for this purpose and their use has been associated with several drawbacks. The aim of this study was to close
PMVSDs in children using a new device the Amplatzer asymmetric ventricular septal defect occluder (AAVSDO).
Methods: Thirteen patients, aged 1.5 to 14 years, with PMVSDs underwent transcatheter closure using the AAVSDO. The device consists of two low profile discs made of Nitinol we mesh with a 1.5 mm connecting waist. The leftsided disc is 5 mm towards the apex and only % mm towards the aortic valve. The rightsided disc is 4 mm larger than the waist. The prosthesis size (waist diameter) was chosen to be 1 2 mm larger than the PMVSD diameter. A 7F or an 8F sheath was used for the delivery of the AAVSDO. Fluoroscopy and transesophageal echocardiography were used for the gwdance of the procedure. Results: The PMVSD diameters ranged from 2 to 8mm. The device diameters ranged from 4 to 10 mm.Overall total occlusion rate was 92.3%. The main complication was embolization of the device in 1 / 13 patients. Method: Transcatheter patch occlusion was attempted in 9 perimembranous VSDs. Eight of the defects had significant L-R shunts (Qp:Qs larger than 2:1) and one Fallot Tetralogy case significant R-L shunt ( Qp:QS 0.9:l. 02 sat 72%).
The size of the defects varied between 4-16 mm (med.8 mm) and the distance from the defect to the right aoriic cusp 1-5mm (med.3mm). Patient age and weight was 2-12yrs (med 7 yrs) and 9-20 kgs (med 15 kg) respectively.
Results: All implantations were successful and resulted in immediate full occlusions. In one case, the patch moved during release and was retrieved. In 8 cases the supl;orting balloons were retrieved in 24(2) to 48(6) hours, resulting in full occlusions in 716 cases. Symptoms were improved and the 02
